This product is for research use only, not for human use. We do not sell to patients.
Size | Price | Stock |
---|---|---|
10g | $400 | Check With Us |
25g | $750 | Check With Us |
50g | $1125 | Check With Us |
Cat #: V32716 CAS #: 14919-77-8 Purity ≥ 99%
Description: Benserazide HCl (Ro-44602; Serazide; Ro 4-4602), the hydrochloride salt of Benserazide, is a carbohydrazide-based, peripherally acting inhibitor of aromatic L-amino acid decarboxylase/AADC or DOPA decarboxylase and a medication used in combination with levodopa (madopar) to treat Parkinson's disease, parkinsonism, and restless leg syndrome.
Publications Citing InvivoChem Products
Product Promise
- Physicochemical and Storage Information
- Protocol
- Related Biological Data
- Stock Solution Preparation
- Quality Control Documentation
Molecular Weight (MW) | 293.70 |
---|---|
Molecular Formula | C10H16ClN3O5 |
CAS No. | 14919-77-8 |
Synonyms | Benserazide hydrochloride; Serazide; Ro 4-4602 |
Protocol | In Vitro | Benserazide hydrochloride (BH) and Levodopa (LD) individually and in combination (Benserazide hydrochloride + LD) (25 μM; 0 hour, 12 hours, 24 hours and 168 hours; SH-SY5Y) treatment inhibit protein aggregation and have the ability to minimise the amyloid-induced cytotoxicity in human neuroblastoma cell line. Benserazide hydrochloride and LD both can act as efficient inhibitors of the formation of cytotoxic HSA aggregates, and the inhibitory effects are more pronounced when both of these drugs are added simultaneously. |
---|---|---|
In Vivo | Benserazide (5-50 mg/kg; intraperitoneal injection; male Wistar rats) treatment of 6-OHDA-lesioned rats increases exogenous L-DOPA-derived extracellular DA levels, the time to reach the peak DA levels are significantly prolong by Benserazide dose-dependently. The AADC activity in the denervates striatal tissues shows a significant decrease by 10 mg/kg and 50 mg/kg Benserazide. Benserazide reduces the central AADC activity in the striatum of rats with nigrostriatal denervation, which leads to changes in the metabolism of exogenous L-DOPA. |
Solvent volume to be added | Mass (the weight of a compound) | |||
---|---|---|---|---|
Mother liquor concentration | 1mg | 5mg | 10mg | 20mg |
1mM | 3.4048 mL | 17.0242 mL | 34.0483 mL | 68.0967 mL |
5mM | 0.6810 mL | 3.4048 mL | 6.8097 mL | 13.6193 mL |
10mM | 0.3405 mL | 1.7024 mL | 3.4048 mL | 6.8097 mL |
20mM | 0.1702 mL | 0.8512 mL | 1.7024 mL | 3.4048 mL |
This equation is commonly abbreviated as: C1 V1 = C2 V2
- (1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
- (2) Be sure to add the solvent(s) in order.